Tecan Group TECN.SW
SwitzerlandHealthcare · Medical Instruments & SuppliesSIX Swiss Exchange · CHF
203.22 CHF (−15.0%)
8 analysts
XTB1.00 €affiliateOpen account ↗
Interactive Brokers7.04 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗Interactive Brokers7.04 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Tecan Group AG is a Swiss provider of laboratory instruments and automation solutions for in vitro diagnostics and life sciences, selling to research laboratories, pharmaceutical companies, and clinical diagnostics.
Listed on SIX Swiss Exchange · Symbol TECN.SW · SWX: TECN · Currency CHF
Key points
from its scores- ✓Good share-price trend8.5
- ✕Weak growth1.5
- ✕Demanding valuation2.6
- ✕Little competitive advantage3.3
AI analysis
bottom line, main risk, context and newsBalance sheet strength and positive momentum do not offset weak profitability and a demanding valuation in a rising rate environment.
Tecan Group shows a solid balance sheet with net cash (Net Debt/EBITDA of -0.14) and good momentum (36.76% over 12 months), but its quality is weak (ROE -9.69%, operating margin 4.16%) and its demanding valuation (forward P/E 30.88, EV/EBITDA 40.15) does not match negative revenue and earnings growth.
The main risk is the inability to reverse the decline in revenue and earnings (-2.70% and -29.80% respectively) in a medical instruments sector under regulatory and pricing pressure, which could lead to a correction of its premium valuation.
Context and risks
Tecan Group, domiciled in Switzerland, operates in a high institutional quality regulatory environment, but the medical instruments sector faces growing regulatory and pricing pressure in its main markets (US and Europe). The company shows weak operating margins (4.16%) and negative ROE, reflecting a challenging competitive and cost environment that could intensify with the review of healthcare reimbursement policies.
Is Tecan Group stock cheap or expensive?
at the analysis dateOn EV / EBITDA, it trades 177% above the Healthcare median.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| EV / EBITDA | 40.1 | 14.5 | +177% |
| Price / book | 2.6 | 4.1 | −36% |
| Price / sales | 3.4 | 3.4 | −1% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 2.6 out of 10 (median for Healthcare: 4.7).
Average analyst target: 203.22 CHF, −15.0% versus the price.
A premium can be justified if the company is of higher quality or grows faster than its sector: Quality / Moat 3.3 (sector 5.5), Growth 1.5 (sector 6.6).
Classic formulas with standard assumptions (5.0% growth, 8-9% discount rate). Indicative only: they change a lot with the assumptions and are not a recommendation.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- Forward P/E
- 30.9
- EV / EBITDA
- 40.1
- Price / book
- 2.6
- Price / sales
- 3.4
- PEG
- 1.71
- Market cap
- 2.9B CHF
- Enterprise value
- 2.9B CHF
Profitability
- ROE
- −9.7%
- ROA
- 1.4%
- ROIC (approx.)
- 2.7%
- Gross margin
- 34.1%
- Operating margin
- 4.2%
- Net margin
- −13.4%
- Free cash flow
- 48.1M CHF
- FCF yield
- 1.6%
- Cash conversion
- 66%
Solvency
- Total debt
- 214.3M CHF
- Net debt
- −10.2M CHF
- Cash
- 224.5M CHF
- EBITDA
- 73.2M CHF
- Net debt / EBITDA
- −0.14
- Debt / equity
- 19.17
- Current ratio
- 2.32
- Quick ratio
- 1.50
Growth
- Revenue growth
- −2.7%
- Earnings growth
- −29.8%
- EPS (TTM)
- −9.16 CHF
- EPS (forward)
- 7.75 CHF
Dividend
- Dividend yield
- 1.3%
- Payout
- 60.6%
Risk and market
- Beta
- 1.01
- Analyst consensus
- Buy (8)
- Target price
- 203.22 CHF
- 52-week range
- 110.60 – 256.80
Recent news
All TECN.SW news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Tecan Group
Is Tecan Group stock cheap or expensive?
On EV / EBITDA, it trades 177% above the Healthcare median. Valuation score: 2.6 out of 10 (median for Healthcare: 4.7). Average analyst target: 203.22 CHF, −15.0% versus the price. This is not investment advice.
What score does Tecan Group get on MeridIAn Screener?
It scores 4.3 out of 10, rank 1,926 of 2,130 (better than 9% of the companies analysed). Its strongest category is Momentum (8.5) and its weakest, Growth (1.5). Analysis of 08/10/2026.
How much is Tecan Group worth on the stock market?
Its market capitalisation is 2.9B CHF and its enterprise value, debt included, is 2.9B CHF.
How much debt does Tecan Group have?
It has more cash than debt: net cash of 10.2M CHF.
Does Tecan Group pay a dividend?
Yes: its dividend yield is 1.25% and it pays out 61% of its earnings.
How has Tecan Group stock performed over the last year?
It has risen 64.4% over the last year, excluding dividends. Over the last 52 weeks it has traded between 110.60 and 256.80 CHF. Past performance does not guarantee future results.
What do analysts think of Tecan Group?
8 analysts cover it; their average recommendation is “Buy” and their average target is 203.22 CHF (−15.0% versus the price). It is an estimate, not market data.